Evidence map›Paper›PMID 42031070›Full record

ArticleMolecular & cellular proteomics : MCP2026

Surfaceome Capture by Multiplex Biotinylation Enables Enhanced Identification of Cell Surface Proteins by Mass Spectrometry.

Ana Levi, Tommy Shields, Irbaz I Badshah, Vinothini Rajeeve, Pedro R Cutillas

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ana LeviCell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, United Kingdom. Electronic address: a.levi@qmul.ac.uk.
Tommy ShieldsCell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, United Kingdom.
Irbaz I BadshahCell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, United Kingdom.
Vinothini RajeeveCell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, United Kingdom.
Pedro R CutillasCell Signalling & Proteomics Group, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, United Kingdom; Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas, CSIC, Granada, Spain. Electronic address: prcutillas@ipb.csic.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A key goal of surfaceomic discovery technologies is to comprehensively interrogate the cell surface proteome to identify targets for immunotherapy development. Considerable progress has made in the application of surfaceomics to profile cancer cells. However, challenges still exist in the sensitivity of current surfaceomic approaches, which consequently, are restricted to the analysis of cell lines or primary tumour material that contain a relatively large number of cells. In addition, since current approaches are based on labelling a single functional group on polypeptides, it is not clear if these recover the full spectrum of proteins present on cell surfaces. To circumvent these limitations, we developed a biotinylation-based combinatory approach for isolating a more diverse group of proteins facing the cell periphery. Our proposed approach, named Surfaceome Capture by Multiplex (SUCAM) biotinylation consists of "multiplexing" biotin reagents to enable for multiple-functional group derivatisation of the surface proteome. LC-MS/MS is then used to identify and characterize proteins pulled down by streptavidin magnetic beads. We found that SUCAM identified more plasma membrane and cell surface proteins than methods based on labelling with single reagents, leading to enhanced identification of cell surface proteins from just 1.2 million cells. Replicate experiments revealed that surfaceomic proteins could be quantified with good precision across repeats (coefficient of variation of 1.7% on average). Application of the approach to a panel of leukaemia cell lines identified well-known leukemic cell surface antigens, as well as proteins with hitherto uncharacterised roles in this disease. SUCAM is a complementary biotinylating strategy that will facilitate surfaceomic profiling for discovery of therapeutic targets in haematological and solid tumours.

Indexed as

Membrane ProteinsProteomicsBiotinylationCell Line, TumorHumansLiquid Chromatography-Mass SpectrometryProteomeTandem Mass SpectrometryMembrane ProteinsProteomecancerdrug targetimmunotherapyleukaemiaquantitative proteomicssurfaceomics

Identifiers

PMID42031070
PMCPMC13202573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.